Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03714828 · ClinicalTrials.gov registry record · Phase 2
Study of TVEC in Patients With Cutaneous Squamous Cell Cancer
A Phase 2 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT03714828: Completed Phase 2 study, sponsored by University of Arizona.
NCT03714828 is a Phase 2 study that has completed, run by University of Arizona. The registered enrollment target is 11 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03714828, a Phase 2 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is single arm Phase 2, single center study of talimogene laherparepvec (TVEC) to treat low risk cutaneous squamous cell carcinomas (cSCC).
Primary Outcome
The primary end point is to evaluate the overall response rate (ORR) defined as proportion of subjects who achieved complete response (CR) and partial response (PR) in the cSCC Target injected lesions (TILs).
Interventions
- DRUG Injection of TVEC into target lesions - week 1-2
- DRUG Injection of TVEC into target lesions 3wks after 1st injection
- DRUG Injection of TVEC into target lesions 2wks after 2nd injection
- DRUG Injection of TVEC into target lesions 2wks after 3rd injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-12-20 |
| Est. Completion | 2023-07-19 |
| Phase | Phase 2 |
What the finished NCT03714828 record still lists
NCT03714828 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 4 interventions - of which Injection of TVEC into target lesions - week 1-2 is the first listed.
NCT03714828 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03714828 about?
NCT03714828 is a clinical study titled "Study of TVEC in Patients With Cutaneous Squamous Cell Cancer". This is single arm Phase 2, single center study of talimogene laherparepvec (TVEC) to treat low risk cutaneous squamous cell carcinomas (cSCC).
What is the current status of trial NCT03714828?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2018-12-20. Estimated completion is 2023-07-19.
What interventions are being tested in trial NCT03714828?
The interventions under investigation include: Injection of TVEC into target lesions - week 1-2 (DRUG), Injection of TVEC into target lesions 3wks after 1st injection (DRUG), Injection of TVEC into target lesions 2wks after 2nd injection (DRUG), Injection of TVEC into target lesions 2wks after 3rd injection (DRUG).
Who is sponsoring clinical trial NCT03714828?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03714828's enrollment target sits among peer trials
11 1967th of 2000 higher than 33 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI